HOME >> MEDICINE >> NEWS
ENBREL (Etanercept) Patient And Physician Support Web Site Launched

Web Site Offers Important Information And Support Programs For People With Rheumatoid Arthritis And For Their Health Care Providers

SEATTLE, April 6, 1999 - In an effort to better educate patients and health care providers about ENBREL (etanercept), a breakthrough treatment for rheumatoid arthritis (RA), Immunex Corporation and Wyeth-Ayerst Pharmaceuticals have launched the ENBREL Web Site: www.enbrel.com. ENBREL is used to treat moderately to severely active rheumatoid arthritis in people who have not adequately responded to one or more disease-modifying anti-rheumatic drugs (DMARDs).

The comprehensive internet site explains how ENBREL works in the body, offers a question and answer section, provides an interactive quiz to help RA sufferers and their doctors determine if ENBREL may be right for them, and highlights several patients' personal experiences with ENBREL. Color photography and animation add to the graphic interest of the site.

Enbrel.com also offers two toll-free numbers to provide support to patients who are considering or are currently taking ENBREL. For questions about insurance coverage, patients can call the Reimbursement Support Line (1-800-282-7704) where they will be connected with an insurance specialist. To answer any noninsurance questions about ENBREL and RA in general, trained telephone counselors are available at 1-888-4ENBREL. A link to the Arthritis Foundation Web Site is also provided.

Approximately 2.1 million Americans suffer from rheumatoid arthritis, an autoimmune disease that can strike at any age and affects three times as many women as men. ENBREL is the first in a class of rheumatoid arthritis drugs known as biologic response modifiers (BRMs), a new approach to RA management and the first breakthrough treatment in many years for people with rheumatoid arthritis.

In medical studies, just over one third of people treated with ENBREL (etanercept) rep
'"/>

Contact: Tim Warner
warnert@immunex.com
206-470-4193
Immunex Corporation
6-Apr-1999


Page: 1 2

Related medicine news :

1. ENBREL (etanercept) long-term clinical trial data
2. ENBREL application for early, active rheumatoid arthritis filed with the U.S. Food and Drug Administration
3. Circulation publishes phase I study of ENBREL in patients with chronic heart failure
4. ENBREL (Etanercept) Receives FDA Approval For Treatment Of Juvenile Rheumatoid Arthritis
5. Positive Results Of Pivotal Phase III Trial With ENBREL In Patients With Early, Active Rheumatoid Arthritis
6. ENBREL Phase III Data Published In Annals Of Internal Medicine
7. Patients newly diagnosed with HIV are more likely to enter outpatient care with case management
8. Patient with drug-resistant form of HIV identified
9. Patient knows best when it comes to ulcerative colitis, U-M study finds
10. Patients with cancer have highly increased risk for blood clots
11. Patients with previous heart attacks may not benefit from pacemaker implant

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: ENBREL Etanercept Patient And Physician Support Web Site Launched

(Date:5/23/2015)... With the implementation of the Affordable Care ... difficult to provide their employees with a viable healthcare ... for employees stand to face strict penalties. Never before ... of a business’s success or failure. In an effort ... Doctors has created a varying level of less expensive ...
(Date:5/23/2015)... May 23, 2015 Javon Bea ... the Sports Medicine and Rehabilitation Center, 557 N. Washington ... Mondays, June 1-July 20, 5:30-6:30 pm. , The 8-week ... and Laurie Finke, RN, BSN, who will offer training ... on nutrition, running mechanics and show selection and weekly ...
(Date:5/22/2015)... CA (PRWEB) May 22, 2015 The ... two exciting events in June. They will hold a ... Doctorate and a two-day class on Classical Chinese Medicine. ... June 3, Dr. Steve Given, the Dean of Clinical ... discuss the new First Professional Doctorate program. ACTCM is ...
(Date:5/22/2015)... 22, 2015 Omar Ahmad Barrada, a ... participate in the 2015 Congress of Future Medical Leaders ... a gathering of “America’s highest achieving high school students.” ... healthcare, set new goals and learn better study habits,” ... surgery, during which we can ask the surgeons questions.” ...
(Date:5/22/2015)... 22, 2015 Carnegie Science Center ... announced a new partnership to develop BodyTech, a dynamic, ... The initiative includes a new exhibit at the Science ... theater, and a new traveling science show, Anatomy Adventure, ... 2015. , Designed to explore a wide range ...
Breaking Medicine News(10 mins):Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 2Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 3Health News:ACTCM Announces Upcoming June Events 2Health News:Milton Hershey School Student Chosen for Congress of Future Medical Leaders 2Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 2Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 3Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 4
(Date:5/22/2015)... 22, 2015 /CNW/ - More than fifty years ago, Thalidomide ... sickness in expectant mothers. Tragically, Thalidomide caused serious and permanent ... Support has been provided to survivors over the ... Canada in 1991 and settlements from drug ... legal obligation to provide support, we have a clear moral ...
(Date:5/22/2015)... May 22, 2015 The leading companies ... billion global cardiac rhythm management device market dominate ... that Medtronic, St. Jude Medical, Boston Scientific and ... this market segment. The healthcare market research publisher,s ... uses 2015 as a base year, providing forecasts ...
(Date:5/22/2015)... 22, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ... publication of the results of the Company,s 72-patient, ... eye drops) for the treatment of dry eye ... ® ) model.  The exploratory study was completed ... previously disseminated by the Company in a press ...
Breaking Medicine Technology:Statement from Minister Ambrose on Thalidomide 2Statement from Minister Ambrose on Thalidomide 3Kalorama: Top Companies Dominate Cardiac Defibrillator Market 2Kalorama: Top Companies Dominate Cardiac Defibrillator Market 3Kalorama: Top Companies Dominate Cardiac Defibrillator Market 4Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 2Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 3Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 4
Cached News: